ASCO 2016: Dr. Susan O’Brien on GDC-0853, a novel BTK inhibitor for CLL

[bkoffman]

Hi,

Well, I’m packing my bags again in preparation to speak at the European School of Hematology meeting being held in Portugal in front of 400 hematologists on what American patients need and want this coming weekend. Then I will take a few days R&R before heading back to what looks to be a really busy fall. Busy is good- I guess. Honestly I don’t want to complain, but I am weary from all my travels.

This week in the Conference Coverage section, we’ve posted an interview with Dr. Susan O’Brien out of UCI where we discussed an interesting abstract from ASCO 2016. It presents the pre-clinical data for a new molecule, GDC-0853 that has different way to bind to and block the BTK pathway, the same pathway that ibrutinib blocks. You can view that short interview here. cllsociety.org/2016/09/asco...

We are excited to announce that we are helping to start a new CLL Patient & Caregiver Support and Education Group in partnership with the Levine Cancer Institute – Morehead in Charlotte, North Carolina. The first meeting will take place on Tuesday, October 18th at 6:30 PM. Patients and family caregivers are welcome. Find out more about dates and registration at cllsociety.org/docs/CLL%20P...

Stay strong.

We are all in this together.

Brian

cllsociety.org

bkoffman.blogspot.com

[Justasheet1]

Doc,

Safe travels and thank you for all you do.

The interview with Dr. O'Brien was fascinating. They need to address the resistance and Richters issues with the BTK inhibitors.

Jeff

[bkoffman CLL CURE Hero in reply to Justasheet1]

I think the spike in RT was found in earlier trials was due to the heavily treated patients living linger and their CLL being controlled. It has been less of an issue since.

[Justasheet1 in reply to bkoffman]

Doc,

Reassuring coming from you. You practice good medicine. Mental health in my case. 😃

Jeff